Literature DB >> 27540020

Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension.

Chandran Nagaraj1, Bi Tang2, Bence M Nagy3, Rita Papp4, Pritesh P Jain4, Leigh M Marsh4, Andrea L Meredith5, Bahil Ghanim6, Walter Klepetko6, Grazyna Kwapiszewska1, E Kenneth Weir7, Horst Olschewski8, Andrea Olschewski9.   

Abstract

Cardioprotective benefits of ω-3 fatty acids such as docosahexaenoic acid (DHA) are well established, but the regulatory effect of DHA on vascular tone and pressure in pulmonary hypertension is largely unknown.As DHA is a potent regulator of K+ channels, we hypothesised that DHA modulates the membrane potential of pulmonary artery smooth muscle cells (PASMCs) through K+ channels and thus exerts its effects on pulmonary vascular tone and pressure.We show that DHA caused dose-dependent activation of the calcium-activated K+ (KCa) current in primary human PASMCs and endothelium-dependent relaxation of pulmonary arteries. This vasodilation was significantly diminished in KCa-/- (Kcnma1-/-) mice. In vivo, acute DHA returned the right ventricular systolic pressure in the chronic hypoxia-induced pulmonary hypertension animal model to the level of normoxic animals. Interestingly, in idiopathic pulmonary arterial hypertension the KCa channels and their subunits were upregulated. DHA activated KCa channels in these human PASMCs and hyperpolarised the membrane potential of the idiopathic pulmonary arterial hypertension PASMCs to that of the PASMCs from healthy donors.Our findings indicate that DHA activates PASMC KCa channels leading to vasorelaxation in pulmonary hypertension. This effect might provide a molecular explanation for the previously undescribed role of DHA as an acute vasodilator in pulmonary hypertension.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27540020      PMCID: PMC5470640          DOI: 10.1183/13993003.01814-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  35 in total

1.  Docosahexaenoic acid monoacylglyceride decreases endothelin-1 induced Ca(2+) sensitivity and proliferation in human pulmonary arteries.

Authors:  Caroline Morin; Samuel Fortin; Eric Rousseau
Journal:  Am J Hypertens       Date:  2012-04-26       Impact factor: 2.689

2.  Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels.

Authors:  M T Nelson; Y Huang; J E Brayden; J Hescheler; N B Standen
Journal:  Nature       Date:  1990-04-19       Impact factor: 49.962

Review 3.  Ion channels and transporters as therapeutic targets in the pulmonary circulation.

Authors:  Andrea Olschewski; Rita Papp; Chandran Nagaraj; Horst Olschewski
Journal:  Pharmacol Ther       Date:  2014-08-06       Impact factor: 12.310

4.  Effect of dietary fish oil on lung lipid profile and hypoxic pulmonary hypertension.

Authors:  S L Archer; G J Johnson; R L Gebhard; W L Castleman; A S Levine; J Y Westcott; N F Voelkel; D P Nelson; E K Weir
Journal:  J Appl Physiol (1985)       Date:  1989-04

5.  Pergolide is an inhibitor of voltage-gated potassium channels, including Kv1.5, and causes pulmonary vasoconstriction.

Authors:  Zhigang Hong; Andrew J Smith; Stephen L Archer; Xi-Chen Wu; Daniel P Nelson; Douglas Peterson; Gerhard Johnson; E Kenneth Weir
Journal:  Circulation       Date:  2005-08-29       Impact factor: 29.690

6.  Chronic hypoxia alters effects of endothelin and angiotensin on K+ currents in pulmonary arterial myocytes.

Authors:  L A Shimoda; J T Sylvester; J S Sham
Journal:  Am J Physiol       Date:  1999-09

7.  Omega-3 fatty acids lower blood pressure by directly activating large-conductance Ca²⁺-dependent K⁺ channels.

Authors:  Toshinori Hoshi; Bianka Wissuwa; Yutao Tian; Nobuyoshi Tajima; Rong Xu; Michael Bauer; Stefan H Heinemann; Shangwei Hou
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

Review 8.  Prostanoid therapy for pulmonary arterial hypertension.

Authors:  David B Badesch; Vallerie V McLaughlin; Marion Delcroix; Carmine Dario Vizza; Horst Olschewski; Olivier Sitbon; Robyn J Barst
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

Review 9.  Prostacyclin therapies for the treatment of pulmonary arterial hypertension.

Authors:  M Gomberg-Maitland; H Olschewski
Journal:  Eur Respir J       Date:  2008-04       Impact factor: 16.671

10.  Docosahexaenoic acid-induced unfolded protein response, cell cycle arrest, and apoptosis in vascular smooth muscle cells are triggered by Ca²⁺-dependent induction of oxidative stress.

Authors:  Slaven Crnkovic; Monika Riederer; Margarete Lechleitner; Seth Hallström; Roland Malli; Wolfgang F Graier; Jörg Lindenmann; Helmut Popper; Horst Olschewski; Andrea Olschewski; Saša Frank
Journal:  Free Radic Biol Med       Date:  2012-03-03       Impact factor: 7.376

View more
  11 in total

1.  MicroRNA-mediated downregulation of K+ channels in pulmonary arterial hypertension.

Authors:  Aleksandra Babicheva; Ramon J Ayon; Tengteng Zhao; Jose F Ek Vitorin; Nicole M Pohl; Aya Yamamura; Hisao Yamamura; Brooke A Quinton; Manqing Ba; Linda Wu; Keeley S Ravellette; Shamin Rahimi; Francesca Balistrieri; Angela Harrington; Rebecca R Vanderpool; Patricia A Thistlethwaite; Ayako Makino; Jason X-J Yuan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-25       Impact factor: 5.464

2.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

Review 3.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

Review 4.  Ion Channels in Pulmonary Hypertension: A Therapeutic Interest?

Authors:  Mélanie Lambert; Véronique Capuano; Andrea Olschewski; Jessica Sabourin; Chandran Nagaraj; Barbara Girerd; Jason Weatherald; Marc Humbert; Fabrice Antigny
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

Review 5.  KCNMA1-linked channelopathy.

Authors:  Cole S Bailey; Hans J Moldenhauer; Su Mi Park; Sotirios Keros; Andrea L Meredith
Journal:  J Gen Physiol       Date:  2019-08-19       Impact factor: 4.086

6.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.

Authors:  Marc Humbert; Christophe Guignabert; Sébastien Bonnet; Peter Dorfmüller; James R Klinger; Mark R Nicolls; Andrea J Olschewski; Soni S Pullamsetti; Ralph T Schermuly; Kurt R Stenmark; Marlene Rabinovitch
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 7.  Revisiting the Large-Conductance Calcium-Activated Potassium (BKCa) Channels in the Pulmonary Circulation.

Authors:  Divya Guntur; Horst Olschewski; Péter Enyedi; Réka Csáki; Andrea Olschewski; Chandran Nagaraj
Journal:  Biomolecules       Date:  2021-11-03

8.  The effect of docosahexaenoic acid on predicting the survival of patients with idiopathic pulmonary arterial hypertension.

Authors:  Xu Huai; Yuanyuan Sun; Xiuying Sun; Wenhui Wu; Lan Wang; Rong Jiang; Sugang Gong; Jinling Li; Yuqing Miao; Ping Yuan; Qinhua Zhao
Journal:  Ann Transl Med       Date:  2021-06

Review 9.  Nutraceuticals in the Treatment of Pulmonary Arterial Hypertension.

Authors:  José L Sánchez-Gloria; Horacio Osorio-Alonso; Abraham S Arellano-Buendía; Roxana Carbó; Adrián Hernández-Díazcouder; Carlos A Guzmán-Martín; Ivan Rubio-Gayosso; Fausto Sánchez-Muñoz
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

10.  Transcriptomic profile of cationic channels in human pulmonary arterial hypertension.

Authors:  Francisco Perez-Vizcaino; Angel Cogolludo; Gema Mondejar-Parreño
Journal:  Sci Rep       Date:  2021-08-04       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.